伊匹木单抗联合同步放化疗后纳武利尤单抗治疗3期不可切除非小细胞肺癌的1/2期研究中的剂量限制性肺毒性
这项多机构前瞻性1/2期试验在19例不可切除III期NSCLC患者中评估同步伊匹木单抗联合放化疗后纳武利尤单抗维持治疗的安全性,因不可接受的毒性提前终止,未进入2期。16例(84%)出现≥3级可能治疗相关毒性,最常见为肺部不良事件(8例,42%),5例发生5级不良事件(其中3例为5级肺部不良事件)。尽管毒性显著,中位无进展生存期为19.2个月(95%CI 6.1-未达到),中位总生存期未达到(95%CI 6.1-未达到),中位随访30.1个月。
要点
- 同步伊匹木单抗联合放化疗后纳武利尤单抗维持治疗因不可接受的毒性提前终止,未进入2期。
- 16例(84%)出现≥3级可能治疗相关毒性,最常见为肺部不良事件(8例,42%)。
- 5例发生5级不良事件,其中3例为5级肺部不良事件。
核心结论
- 同步伊匹木单抗联合放化疗治疗不可切除III期NSCLC与肺毒性相关,可能限制改善结局的机会。
- 未来旨在将伊匹木单抗或其他抗CTLA4疗法纳入不可切除III期NSCLC管理的研究应考虑谨慎措施以最小化毒性风险。
研究设计与样本
- 多机构前瞻性1/2期试验,纳入不可切除III期NSCLC患者,计划评估安全性(1期)和12个月无进展生存期(2期)。
- 治疗方案包括铂类双药化疗联合胸部放疗60 Gy分30次,伊匹木单抗(1 mg/kg)在第1周和第4周给药,放化疗后纳武利尤单抗(480 mg)每4周一次最多12个周期。
- 不良事件按CTCAE 5.0版评估,生存分析采用Kaplan-Meier法和log-rank检验。
主要发现
- 试验在纳入19例患者后因不可接受的毒性提前终止,未进入2期。
- 16例(84%)出现≥3级可能治疗相关毒性,最常见为肺部不良事件(n=8,42%)。
- 14例(74%)因不良事件(n=12,63%)或患者选择(n=2,11%)提前终止研究治疗。
- 11例(58%)发生≥2级肺毒性,中位发生时间4.1个月(95%CI 2.6-未达到),12个月无≥2级肺毒性生存率37%(95%CI 16-59)。
- 5例发生5级不良事件,包括3例5级肺部不良事件(1例呼吸衰竭伴肺炎和肺栓塞,1例肺炎/慢性阻塞性肺疾病急性加重,1例肺纤维化)。
局限性
- 试验因不可接受的毒性提前终止,未进入2期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We hypothesized that concurrent ipilimumab with chemoradiationtherapy (chemoRT) followed by maintenance nivolumab would be safe for patients with unresectable stage III non-small cell lung cancer (NSCLC). We aimed to assess the safety (phase 1) and the 12-month progression-free survival (PFS) (phase 2) in a multi-institution prospective trial. METHODS AND MATERIALS: Eligible patients had unresectable stage III NSCLC. The treatment included platinum doublet chemotherapy with concurrent thoracic radiation therapy to 60 Gy in 30 fractions and ipilimumab (1 mg/kg) delivered during weeks 1 and 4. After chemoRT, maintenance nivolumab (480 mg) was given every 4 weeks for up to 12 cycles. Adverse events (AEs) were assessed according to the Common Terminology Criteria for Adverse Events, version 5.0. Survival analyses were performed with Kaplan Meier (KM) methods and log-rank tests. RESULTS: The trial was discontinued early after enrolling 19 patients without proceeding to the phase 2 component because of unacceptable toxicity. Sixteen patients (84%) had grade ≥3 (G3+) possible treatment-related toxicity, most commonly pulmonary AEs (n = 8, 42%). Fourteen patients (74%) discontinued study therapy early because of AEs (n = 12, 63%) or patient choice (n = 2, 11%). Eleven patients (58%) experienced G2+ pulmonary toxicity with median time to onset 4.1 months (95% CI 2.6-not reached [NR]), and 12-month freedom from G2+ pulmonary toxicity 37% (95% CI, 16-59). Five patients had G5 AEs, including 3 with G5 pulmonary AEs (1 respiratory failure with pneumonitis and pulmonary embolism, 1 pneumonia/chronic obstructive pulmonary disease exacerbation, 1 pulmonary fibrosis). Despite toxicities, the median PFS was 19.2 months (95% CI 6.1-NR) and the median overall survival was NR (95% CI 6.1-NR) with median follow-up of 30.1 months by the reverse KM method. CONCLUSIONS: Concurrent ipilimumab with chemoRT for unresectable stage III NSCLC is associated with pulmonary toxicity that may limit opportunities for improved outcomes. Future studies aiming to incorporate ipilimumab or other anti-CTLA4 therapies into management of unresectable stage III NSCLC should consider careful measures to minimize toxicity risk.
引用
- Liveringhouse CL, Latifi K, Asous AG, et al. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 36657497. doi:10.1016/j.ijrobp.2023.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。